A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Overview

Información sobre este estudio

The purpose of this study with a 28-week Open-label Extension of BLU-5937 in adult (18 to 80 years of age) participants who have had persistent cough for ≥ 1 year prior to Screening, with a diagnosis of RCC defined as:

  • insufficient improvement in cough after treatment for the underlying condition(s) causing the cough; OR
  • unexplained cough for which an underlying condition has not been determined despite adequate investigation with diagnostic tests and trials of therapy.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Capable of giving signed informed consent.
  • Refractory chronic cough (including unexplained chronic cough) for at least one year.
  • Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose.

Exclusion Criteria:

  • Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with > 20 pack-year smoking history.
  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma.
  • Respiratory tract infection within 4 weeks before screening.
  • Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening.
  • History of malignancy in the last 5 years.
  • History of alcohol or drug abuse within the last 3 years.
  • Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
  • Previous participation in a BLU-5937 trial.

Eligibility last updated 2/16/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Vivek Iyer, M.D., M.P.H.

Abierto para la inscripción

Contact information:

Sue Ann Donlinger

(507) 284-9259

Donlinger.SueAnn@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20545526

Mayo Clinic Footer